Komal Jhaveri, MD, clinical director for early drug development service at Memorial Sloan Kettering Cancer Center, and Julie Nangia, MD, medical director of breast oncology at Baylor College of Medicine, discuss a randomized phase 3 study of datopotamab deruxtecan vs chemotherapy — how does this trial change our treatment algorithm?
▷ Estimated Read Time:
1–2 minutes
SABCS Snippets: TROPION-Breast01
Join the global breast cancer community for four days of research spanning experimental biology, etiology, translational science, prevention, diagnosis and treatment, December 8-11 in San Antonio, Texas.
Share: